Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)

Trial Profile

Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms LUPSENIC
  • Most Recent Events

    • 05 Feb 2016 Status changed from recruiting to discontinued.
    • 29 Aug 2013 Planned end date changed from 1 Jun 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 27 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top